FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1925661138> ?p ?o ?g. }

• W1925661138 abstract "Background. We recently identified an in-frame ESR1 translocation in a tumor and PDX pair from a patient with endocrine therapy resistant advanced disease. The fusion gene preserved the N-terminal 365aa of ESR1 containing the intact activation function 1 (AF1), DNA-binding domain (DBD) and hinge, followed by the C-terminal transactivation domain of YAP1. The ESR1-365>YAP1 fusion drove estrogen-independent and anti-estrogen-resistant tumor cell growth (Cell Reports 4:1116, 2013). We therefore sought to further investigate the role of ESR1 fusion genes in breast cancer. Methods . 711 cases from TCGA, 82 ER+ cases from neoadjuvant endocrine therapy trials and 25 ER+ systemic relapse samples were screened for fusion genes using RNAseq. Fusion genes involving ESR1 were subsequently assayed for estrogen response element (ERE)-mediated transcriptional activity and ability to drive estradiol independent breast cancer cell growth. Results. Multiple ESR1 fusions were identified in mostly luminal B cancers. ESR1 fusions resulted most frequently from rearrangements involving another gene on Chromosome (Chr) 6 but also fusions with genes on other chromosomes. The fusions involving partners on Chr6 that retained an intact N terminal AF1 and DNA binding domain (DBD) of ESR1 (≥1-253aa) included an Out-of-Frame (OF) fusion event with CCDC170 (a gene immediately centromeric to ESR1), POLH (in-frame or IF), AKAP12 (IF), PCMT1 (OF), SYNE1 (OF) and GPR126 (OF). Also identified were inter-chromosomal translocations involving Chr12p-NOP2 (IF) and ChrX-PCDH11X (IF) and Chr7q-AKR1D1 (OF). The ESR1 fusions with transcriptional potential (because of a retained DNA binding domain) included variable 5’ ESR1 exons that preserved 253aa, 365aa, 412aa or 458aa of ESR1 sequence: in all cases disrupting ligand binding though loss of C terminal sequence. The effect of the IF and OF 3’ sequences on the transcriptional activity of the relevant ESR1 fragment was highly variable. The most transcriptionally active fusion (more active than the relevant ESR1 fragment alone) was the ESR1-365>YAP1 as well as ESR1-365>PCDH11X and ESR1-253>CCDC170. This is remarkable since PCDH11X is not considered a transcription factor and the CCDC170 sequence was OF – in both cases suggesting the activity of the fusion was due to neomorphic properties. Two fusions, NOP2 and POLH were inactive in the ERE reporter assay, yet both stimulated estradiol independent growth. In these cases we suggest that the ESR1 locus can function as a promoter trap which allows the identification of genes with previously unknown functions in endocrine therapy resistance. Conclusions: In luminal-type breast cancer the ESR1 gene was fused to multiple 3’ partners with remarkably heterogeneous functions. The two most transcriptionally active, ESR1-365>YAP1 and ESR1-365>PCDH11X, were both identified in endocrine therapy refractory advanced disease – suggesting a role in fatal disease progression. Citation Format: Jieya Shao, Jin Zhang, Robert J Crowder, Rodrigo Goncalves, Chanpheng Phommaly, Breast AWG and Network, Charles M Perou, Christopher A Maher, E Aubrey Thompson, Matthew J Ellis. ESR1 gene fusions implicated in endocrine therapy resistance of ER+ breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PD6-4." @default.
• W1925661138 created "2016-06-24" @default.
• W1925661138 creator A5026692399 @default.
• W1925661138 creator A5028616783 @default.
• W1925661138 creator A5036456967 @default.
• W1925661138 creator A5055174519 @default.
• W1925661138 creator A5057135409 @default.
• W1925661138 creator A5062281803 @default.
• W1925661138 creator A5062498736 @default.
• W1925661138 creator A5078094948 @default.
• W1925661138 creator A5089141937 @default.
• W1925661138 creator A5091346438 @default.
• W1925661138 date "2015-04-30" @default.
• W1925661138 modified "2023-09-27" @default.
• W1925661138 title "Abstract PD6-4: ESR1 gene fusions implicated in endocrine therapy resistance of ER+ breast cancer" @default.
• W1925661138 doi "https://doi.org/10.1158/1538-7445.sabcs14-pd6-4" @default.
• W1925661138 hasPublicationYear "2015" @default.
• W1925661138 type Work @default.
• W1925661138 sameAs 1925661138 @default.
• W1925661138 citedByCount "0" @default.
• W1925661138 crossrefType "proceedings-article" @default.
• W1925661138 hasAuthorship W1925661138A5026692399 @default.
• W1925661138 hasAuthorship W1925661138A5028616783 @default.
• W1925661138 hasAuthorship W1925661138A5036456967 @default.
• W1925661138 hasAuthorship W1925661138A5055174519 @default.
• W1925661138 hasAuthorship W1925661138A5057135409 @default.
• W1925661138 hasAuthorship W1925661138A5062281803 @default.
• W1925661138 hasAuthorship W1925661138A5062498736 @default.
• W1925661138 hasAuthorship W1925661138A5078094948 @default.
• W1925661138 hasAuthorship W1925661138A5089141937 @default.
• W1925661138 hasAuthorship W1925661138A5091346438 @default.
• W1925661138 hasConcept C104317684 @default.
• W1925661138 hasConcept C111829193 @default.
• W1925661138 hasConcept C121608353 @default.
• W1925661138 hasConcept C1292079 @default.
• W1925661138 hasConcept C172313692 @default.
• W1925661138 hasConcept C502942594 @default.
• W1925661138 hasConcept C530470458 @default.
• W1925661138 hasConcept C54355233 @default.
• W1925661138 hasConcept C84606932 @default.
• W1925661138 hasConcept C86339819 @default.
• W1925661138 hasConcept C86803240 @default.
• W1925661138 hasConceptScore W1925661138C104317684 @default.
• W1925661138 hasConceptScore W1925661138C111829193 @default.
• W1925661138 hasConceptScore W1925661138C121608353 @default.
• W1925661138 hasConceptScore W1925661138C1292079 @default.
• W1925661138 hasConceptScore W1925661138C172313692 @default.
• W1925661138 hasConceptScore W1925661138C502942594 @default.
• W1925661138 hasConceptScore W1925661138C530470458 @default.
• W1925661138 hasConceptScore W1925661138C54355233 @default.
• W1925661138 hasConceptScore W1925661138C84606932 @default.
• W1925661138 hasConceptScore W1925661138C86339819 @default.
• W1925661138 hasConceptScore W1925661138C86803240 @default.
• W1925661138 hasLocation W19256611381 @default.
• W1925661138 hasOpenAccess W1925661138 @default.
• W1925661138 hasPrimaryLocation W19256611381 @default.
• W1925661138 hasRelatedWork W20288957 @default.
• W1925661138 hasRelatedWork W2241382 @default.
• W1925661138 hasRelatedWork W24077188 @default.
• W1925661138 hasRelatedWork W26128854 @default.
• W1925661138 hasRelatedWork W34411024 @default.
• W1925661138 hasRelatedWork W34629064 @default.
• W1925661138 hasRelatedWork W37158861 @default.
• W1925661138 hasRelatedWork W40950966 @default.
• W1925661138 hasRelatedWork W43055999 @default.
• W1925661138 hasRelatedWork W6247448 @default.
• W1925661138 isParatext "false" @default.
• W1925661138 isRetracted "false" @default.
• W1925661138 magId "1925661138" @default.
• W1925661138 workType "article" @default.